The problem: a peptide you cannot normally swallow

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that mimics the natural GLP-1 hormone, acting on appetite-regulating areas of the brain to increase satiety, reduce hunger and cut food cravings.[2] The catch is chemistry. Semaglutide is a peptide: a large, delicate molecule that stomach acid and digestive enzymes would ordinarily break down before it reached the bloodstream. That is why the original Wegovy is a once-weekly injection, and why potent GLP-1 medicines were injectables rather than pills for years.[1] Making semaglutide work as a tablet meant solving that absorption problem — the answer was a co-formulated absorption enhancer called SNAC.

What SNAC is, and where it came from

SNAC is short for sodium N-[8-(2-hydroxybenzoyl)amino]caprylate — also known as salcaprozate sodium, and branded Eligen® SNAC. It is co-formulated with semaglutide in the tablet. According to the European Medicines Agency's assessment, SNAC raises the pH locally around the dissolving tablet and transiently makes the stomach lining more permeable to semaglutide, so that some of the drug is absorbed, mainly in the stomach.[7]

Because only a small amount is absorbed, and food or extra water reduce it further, the tablet is taken under strict rules — swallowed whole on an empty stomach with only a little plain water, then a wait before eating, drinking or taking anything else, or too little of the drug is absorbed.[11] Those rules are covered on our Wegovy pill dosage page.

The Emisphere acquisition

The Eligen SNAC platform did not originate inside Novo Nordisk. It came from a company called Emisphere Technologies, with whom Novo Nordisk had collaborated on the technology since 2007.[6] To secure full ownership of the platform underpinning its oral-semaglutide franchise, Novo Nordisk moved to buy Emisphere outright. Novo Nordisk announced the acquisition on 6 November 2020 and completed it on 8 December 2020, giving it full access to the SNAC platform.[6]

Key takeaway

The Wegovy pill exists because two things work together: the active molecule (semaglutide, the same one in the injection) and an absorption technology (Eligen SNAC) that helps a small amount of the peptide be absorbed in the stomach. Novo Nordisk secured that technology by acquiring Emisphere outright in 2020.[6]

From Rybelsus to the Wegovy pill: PIONEER came first

SNAC-based oral semaglutide was not new in 2025. It was first commercialised as Rybelsus, an oral semaglutide tablet licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg once daily[5] — strengths that, in the UK, have since been replaced by a newer formulation at 1.5 mg, 4 mg and 9 mg.[12] The evidence for that use came from Novo Nordisk's PIONEER programme in type 2 diabetes — including PIONEER PLUS, which tested higher research strengths of 25 mg and 50 mg against the established 14 mg dose.[8]

The Wegovy pill is best understood as the higher-dose, weight-management application of that same oral-semaglutide technology: same active molecule, same SNAC delivery, but a distinct product with a 25 mg maintenance dose and a different purpose.[1][5] One thing worth keeping straight is the numbering: Rybelsus originally used a 3/7/14 mg ladder[5] and now uses 1.5/4/9 mg tablets,[12] the Wegovy pill titrates to 25 mg,[1] and the obesity trials used research strengths of 25 mg and 50 mg[3][4] — separate systems that should not be conflated, even where the milligram numbers match.

The OASIS programme: testing the pill for weight loss

The evidence that oral semaglutide could produce meaningful weight loss came from the phase 3 OASIS programme, which tested once-daily oral semaglutide at 25 mg and 50 mg in obesity.[3][4]

OASIS 1 — the earlier 50 mg read-out

OASIS 1 was a 68-week, double-blind, randomised, placebo-controlled trial in adults with overweight or obesity without type 2 diabetes. It tested the 50 mg dose and reported a mean weight change of −15.1% with oral semaglutide versus −2.4% on placebo at week 68. The results were published in The Lancet in 2023.[3] One caveat: 50 mg is not the approved dose. The licensed Wegovy pill is 25 mg, so the on-label efficacy story rests on the later OASIS 4 trial.

OASIS 4 — the trial behind the approved 25 mg pill

OASIS 4 was the approval-supporting trial for the 25 mg strength: a 64-week (71 weeks including a 12-week escalation and 7-week follow-up) phase 3b study of oral semaglutide 25 mg (n=205) against placebo (n=102) — 307 adults with obesity or overweight but without diabetes, alongside lifestyle support. The population was around 79% women, with a mean age of 48.[4][14]

Its two headline weight-loss figures answer slightly different questions, so each carries a statistical "estimand":

  • If fully adhered (the trial-product estimand): mean weight change of −16.6% versus −2.8% on placebo.[1][11]
  • Regardless of adherence (the treatment-policy estimand): mean weight change of −13.6% versus −2.2% on placebo, according to the UK product information.[11]

Around 76% of people on the drug lost at least 5% of body weight, against 31% on placebo.[9] For the larger threshold of at least 20% weight loss, Novo Nordisk describes "one in three" people (the adherent figure), while the treatment-policy figure was 27.5% versus 3% — the same trial viewed through two estimands, not a disagreement.[1][11] BMI, waist circumference, HbA1c, lipids and C-reactive protein also improved versus placebo. OASIS 4 was published in the New England Journal of Medicine on 18 September 2025.[4]

Regulatory milestones

In the United States, the FDA approved the tablet on 22 December 2025 for adults with obesity, or overweight with weight-related medical problems, to lose weight and keep it off alongside a reduced-calorie diet and more physical activity; the US label also carries a cardiovascular indication — reducing the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.[1][9]

In the United Kingdom, the MHRA approved the tablet on 11 June 2026, described as the first oral GLP-1 licensed for weight management in the UK.[2] It held that position alone for two months: on 10 August 2026 the MHRA authorised Foundayo (orforglipron, Eli Lilly) as the UK's second oral GLP-1, and it has been available on private prescription since 24 August 2026.[10] In the European Union, the tablets have since been added to Wegovy's EU-wide authorisation, following a positive opinion from the European Medicines Agency's human medicines committee on 21 May 2026.[13] In UK use the tablet is titrated slowly — a 1.5 mg → 4 mg → 9 mg → 25 mg ladder with a minimum of one month at each step — to limit gastrointestinal side effects during escalation; the full schedule is on our dosage page.[2]

The manufacturing story is really the SNAC story

For the Wegovy pill, the defining manufacturing move was securing the absorption technology rather than building any single plant — which is why the 2020 Emisphere acquisition mattered so much, removing Novo Nordisk's dependence on an outside licensor for the SNAC platform.[6] Detailed production-capacity figures for the 25 mg pill were not established in the sources reviewed for this page, so we do not quote any here.

A note on safety and access

The US labelling carries a boxed warning about a risk of thyroid C-cell tumours, including medullary thyroid carcinoma, based on rodent data — a warning that runs across the semaglutide class.[9] The most commonly reported side effects are gastrointestinal — nausea, diarrhoea, vomiting, constipation and abdominal pain among them — generally mild to moderate and worst during dose escalation, with an overall profile reported as comparable to the injection.[9][11] We set out the warnings, contraindications and precautions on our side effects page. If you experience a side effect from any medicine, report it through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, and speak to your GP or pharmacist.

On access, the point is simple: this is a prescription-only medicine. Lawful UK supply happens only through GPhC-registered pharmacies against a valid prescription, after a consultation in which a prescriber decides whether it is a suitable option — one option a prescriber may discuss, never something anyone must take.

Frequently asked questions

Who makes the Wegovy pill?

Novo Nordisk. The absorption technology it relies on, the Eligen SNAC enhancer, came from Emisphere Technologies — a company Novo Nordisk had collaborated with since 2007 and acquired outright in 2020.[6]

What is SNAC and how does it let semaglutide work as a pill?

SNAC (salcaprozate sodium) is an absorption enhancer co-formulated with semaglutide, a peptide that is poorly absorbed from the gut. According to the European Medicines Agency's assessment, SNAC raises the pH locally around the tablet and transiently makes the stomach lining more permeable to semaglutide. Because only a small amount is absorbed even so, the tablet has strict dosing rules.[7][11]

Is the Wegovy pill the same as Rybelsus?

No. Both are SNAC-based oral semaglutide tablets, but they are different products. Rybelsus is licensed for type 2 diabetes at 1.5 mg, 4 mg or 9 mg once daily (newer tablets that replaced its original 3 mg, 7 mg and 14 mg strengths); the Wegovy pill is a higher-dose oral semaglutide, with a 25 mg maintenance dose, developed for weight management.[5][12]

When was the Wegovy pill approved?

The US FDA approved the tablet on 22 December 2025.[1] The UK MHRA approved it on 11 June 2026, making it the first oral GLP-1 licensed for weight management in the UK. It is a prescription-only medicine.[2]

Further reading

References

  1. Novo Nordisk. FDA approval of the Wegovy pill (oral semaglutide 25 mg) — company announcement. novonordisk.com
  2. Medicines and Healthcare products Regulatory Agency (MHRA) / GOV.UK. "First GLP-1 tablet for weight loss approved in the UK" — press release, 11 June 2026: the UK approval date, the tablet as the first oral GLP-1 licensed for weight management in the UK, the mechanism, and the dose ladder (1.5 mg → 4 mg → 9 mg → 25 mg, minimum one month at each dose). gov.uk
  3. The Lancet. OASIS 1 — oral semaglutide 50 mg in adults with overweight or obesity without type 2 diabetes, 2023. thelancet.com
  4. Wharton S, Lingvay I, Bogdanski P, et al. "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity" (OASIS 4). New England Journal of Medicine, 18 September 2025;393:1077–1087 — design (a 71-week trial, including follow-up, of 205 people on oral semaglutide 25 mg and 102 on placebo) and results. doi.org/10.1056/NEJMoa2500969 Trial registration: ClinicalTrials.gov NCT05564117. clinicaltrials.gov
  5. US Food and Drug Administration. Rybelsus (oral semaglutide) Prescribing Information (2024) — the original 3/7/14 mg strengths and SNAC administration, for comparison. accessdata.fda.gov
  6. Novo Nordisk. "Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology" — company announcement, 6 November 2020 (collaboration since 2007; full access to the Eligen SNAC platform and an end to future royalty obligations). novonordisk.com Also: "Novo Nordisk announces completion of the Emisphere Technologies acquisition", 8 December 2020. novonordisk.com
  7. European Medicines Agency. Wegovy — EPAR assessment report for the tablet extension (X/0000296344), published 26 August 2026: SNAC (salcaprozate sodium) increases pH locally around the tablet and transiently increases the permeability of the stomach lining to semaglutide, which is absorbed mainly in the stomach. ema.europa.eu
  8. Aroda VR, Aberle J, Bardtrum L, et al. "Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial." The Lancet, 2023. doi.org/10.1016/S0140-6736(23)01127-3
  9. US Food and Drug Administration. Wegovy (semaglutide) injection and tablets — US Prescribing Information, revised 06/2026 (via DailyMed): US indications, including reducing the risk of major adverse cardiovascular events; the boxed warning on thyroid C-cell tumours; the common side-effect list and dose escalation to reduce gastrointestinal side effects; and the 25 mg tablet trial result for at least 5% weight loss (76.3% vs 31.3% on placebo). dailymed.nlm.nih.gov
  10. MHRA / GOV.UK. "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes" — Foundayo (orforglipron) authorisation, 10 August 2026; Lilly UK announced private-prescription availability on 24 August 2026. gov.uk
  11. Novo Nordisk. Wegovy 25 mg tablets — UK Summary of Product Characteristics, section 4.2 (on an empty stomach after fasting for at least 8 hours, swallowed whole with a sip of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines), section 4.8 (gastrointestinal side effects most frequent during dose escalation and mostly mild to moderate; safety profile consistent with the semaglutide injection trials), section 5.2 (low oral bioavailability; absorption reduced by food or large volumes of water) and section 5.1, Table 2 (OASIS 4 results at week 64: body-weight change −13.6% vs −2.2% with placebo, and ≥20% weight loss in 27.5% vs 3%, treatment-policy analysis; −16.6% vs −2.8% if all patients had stayed on treatment); text revised 06/2026. medicines.org.uk
  12. Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update, "Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error", 17 December 2025 — new 1.5 mg, 4 mg and 9 mg Rybelsus tablets are bioequivalent to, and replace, the original 3 mg, 7 mg and 14 mg tablets. gov.uk
  13. European Medicines Agency. Wegovy — EPAR overview and assessment history: the EU medicine overview (updated 26 August 2026) now covers tablets as well as pens; CHMP post-authorisation summary of positive opinion for the tablet extension (X/0000296344), adopted 21 May 2026, with the European Commission decision issued on 14 July 2026. ema.europa.eu
  14. ClinicalTrials.gov. NCT05564117 — OASIS 4 record with results: baseline characteristics of the 307 randomised participants (242 female, about 79%; mean age 48 years). clinicaltrials.gov

We link only to regulators, manufacturers, trial registries and peer-reviewed journals, and never to any pharmacy, clinic or retailer.